Earnings summaries and quarterly performance for UFP TECHNOLOGIES.
Executive leadership at UFP TECHNOLOGIES.
R. Jeffrey Bailly
Detailed
Chief Executive Officer
CEO
Christopher P. Litterio
Detailed
General Counsel, Secretary, and Senior Vice President of Human Resources
Jason Holt
Detailed
Vice President and Chief Commercial Officer
Mitchell C. Rock
Detailed
President
Ronald J. Lataille
Detailed
Senior Vice President, Treasurer, and Chief Financial Officer
Board of directors at UFP TECHNOLOGIES.
Research analysts who have asked questions during UFP TECHNOLOGIES earnings calls.
Andrew Cooper
Raymond James
4 questions for UFPT
Also covers: AZTA, CDNA, CTKB +12 more
Brett Fishbin
KeyBanc Capital Markets
4 questions for UFPT
Also covers: ALC, COO, ICUI +6 more
Jaeson Schmidt
Lake Street Capital Markets
4 questions for UFPT
Also covers: AVNW, BHE, BKSY +13 more
Justin Ages
CJS Securities
4 questions for UFPT
Also covers: CR, CVCO, DBD +3 more
Recent press releases and 8-K filings for UFPT.
UFP Technologies Highlights Strong Medtech Growth and Announces CEO Succession
UFPT
Revenue Acceleration/Inflection
Management Change
M&A
- UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient Medtech devices, with current revenue of approximately $600 million. The company has seen its Medtech revenue grow 3x from $132 million in 2021 to $550 million today.
- The company targets annual revenue growth of 12%-18% (half from acquisitions, half internal), gross margins of 28%-31%, and adjusted operating margins of 17%-20%.
- Jeff Bailly, Chairman and CEO, announced his retirement in June next year, with Mitch Rock, the current President, slated to become the new CEO.
- An acquisition, AJR, is experiencing challenges as more than half of its employees were found to be illegal to work in the U.S., requiring replacement and training, which is expected to impact results for a couple more quarters.
3 days ago
UFP Technologies discusses medtech focus, growth strategy, and CEO succession at Piper Sandler conference
UFPT
M&A
CEO Change
Guidance Update
- UFP Technologies (UFPT) is a contract development and manufacturing organization specializing in single-use and single-patient medtech devices, with approximately $600 million in revenue and 5,000 associates across 21 factories in five countries.
- The company has significantly shifted its focus, with $550 million of its $600 million revenue now derived from medtech, and has tripled its revenue over the past four years since 2021.
- UFPT operates with a two-pronged growth strategy combining internal growth through customer-funded development and acquisitions aimed at enhancing value to customers.
- Published growth targets include 12%-18% revenue growth, 28%-31% gross margins, and 17%-20% adjusted operating margins.
- Mitch Rock, current President, is slated to become CEO in June of next year (2026) upon the retirement of current Chairman and CEO Jeff Bailly.
3 days ago
UFP Technologies Discusses Business Model, Growth Strategy, and Leadership Transition
UFPT
M&A
Guidance Update
Management Change
- UFP Technologies, a contract development and manufacturing organization (CDMO) specializing in single-use and single-patient medtech devices, reports approximately $600 million in revenue and operates 21 factories across five countries.
- The company's business is segmented into medical devices (53%), robotic surgery (30%), and sterile packaging (17%), with robotic surgery identified as its largest and fastest-growing market.
- UFP Technologies' growth strategy combines internal growth through customer-funded development with strategic acquisitions, which has led to a 3x increase in revenue over the past four years.
- The company targets 12%-18% revenue growth, 28%-31% gross margins, and 17%-20% adjusted operating margins.
- Mitch Rock, the current President, is slated to become CEO in June 2026, succeeding Jeff Bailly. The company also noted a temporary impact on operations and margins from the AJR acquisition due to employee E-Verification issues.
3 days ago
UFP Technologies Presents Updated Investor Materials Highlighting MedTech Focus and Growth Targets
UFPT
Guidance Update
M&A
Revenue Acceleration/Inflection
- UFP Technologies, Inc. (UFPT) is a contract development and manufacturing organization with approximately 92% of its annual revenue of ~$600 million derived from the MedTech market.
- The company has established 3 to 5 year financial targets, aiming for 12-18% revenue growth, 28-31% gross margin, and 17-20% adjusted operating margin.
- UFPT's growth strategy involves both internal growth within high-growth MedTech segments and strategic acquisitions, having completed 22 acquisitions to date.
- MedTech sales have significantly increased, growing from $132 million in 2021 to $550 million for the trailing twelve months ended Q3 2025.
4 days ago
UFP Technologies Reports Q3 2025 Results Amidst AGR Labor Challenges
UFPT
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- UFP Technologies reported Q3 2025 sales growth of 6.5% to $154.6 million, with its medtech business growing 7.3% despite a 23% decline in patient services and support from its AGR Stryker business.
- The company faced a $3 million reduction in gross profit and operating income and a 28% reduction in diluted EPS in Q3 2025 due to labor inefficiencies at its AGR Illinois facility, which also resulted in over $8 million in unfulfilled orders.
- Robotic surgery revenue increased 5.1%, with two significant new programs expected to generate greater than $10 million in 2026, and discussions are ongoing to extend and significantly increase volumes for a $500 million contract with its largest customer.
- UFP Technologies generated $35.9 million in cash from operations and paid down approximately $17.5 million in debt during Q3 2025, achieving a leverage ratio well below 1.5 times.
Nov 4, 2025, 1:30 PM
UFP Technologies Announces Q3 2025 Results
UFPT
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- UFP Technologies reported Q3 2025 sales of $154.6 million, a 6.5% increase from Q3 2024, with MedTech sales growing 7.3%. Year-to-date sales through September 30, 2025, increased 26.0% to $453.9 million.
- Net income and diluted EPS remained flat at $16.4 million and $2.11, respectively, for Q3 2025 compared to Q3 2024, primarily due to $3 million in incremental labor costs and over $8 million in unfulfilled orders at the Illinois AJR facility.
- The company is advancing strategic initiatives, including the launch of new robotic surgery programs and the transfer of programs to its new Dominican Republic facility, with recent acquisitions performing ahead of expectations.
Nov 3, 2025, 9:16 PM
UFP Technologies Announces Q3 2025 Results
UFPT
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- UFP Technologies reported Q3 2025 sales of $154.6 million, a 6.5% increase from Q3 2024, with year-to-date sales reaching $453.9 million, up 26.0% from the prior year period.
- Net income for Q3 2025 was $16.4 million, or $2.11 per diluted common share, matching Q3 2024 results. Adjusted earnings per diluted share for the quarter were $2.39.
- The company's MedTech sales grew 7.3% to $142.4 million in Q3 2025, while non-medical sales decreased 2.7%.
- Operating results in Q3 2025 were impacted by approximately $3 million in incremental labor costs at the Illinois AJR facility, which offset EPS growth.
Nov 3, 2025, 9:08 PM
UFP Technologies Presents Business Strategy and Financial Targets
UFPT
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- UFP Technologies (UFPT) is a Contract Development Manufacturing Organization (CDMO) in the medical device sector, with a market capitalization of close to $2 billion and $600 million in total revenue, of which $550 million is medical revenue.
- The company operates in a $100 billion medical device outsourcing market, which is growing at 10-11%. UFPT's strategy includes organic growth and strategic acquisitions, having completed 9 deals in the med tech space since 2021, which has driven medical revenue from $132 million in 2021 to $540 million trailing 12 months.
- UFPT provides 3-5 year financial targets of 12% to 18% revenue growth, 28% to 31% gross margins, and 17% to 20% adjusted operating margin, targets it has exceeded in recent years.
- Key differentiators include over 100 engineers providing technical value and strong supplier relationships, operating in a highly regulated space that creates barriers to entry.
Aug 26, 2025, 1:51 PM
Quarterly earnings call transcripts for UFP TECHNOLOGIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more